Cellenkos Wins FDA Clearance for CK0801 Phase 2 Trial
HOUSTON, TEXAS, April 27, 2026 Cellenkos Inc. has received U.S. Food and Drug Administration (FDA) clearance to initiate a...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
HOUSTON, TEXAS, April 27, 2026 Cellenkos Inc. has received U.S. Food and Drug Administration (FDA) clearance to initiate a...
